Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brimonidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 20/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 19/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 19/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 14/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 11/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 12/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | HTR1A | P08908 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brimonidine SCHEMBL27455839 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29356891 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29470063 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL2400529 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL34647 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29378438 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL34649 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL22616168 | 0.99 | ADRA2A (0.98) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL22616169 | 0.99 | ADRA2A (0.98) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29227701 | 0.99 | ADRA2A (0.98) | ADRA2AADRA2BADRA2CADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099435-A1 | TREATMENT OF DIABETIC RETINOPATHY USING ENDOTHELIN RECEPTOR ANTAGONISTS | PERFUSE THERAPEUTICS, INC. | 2025-03-27 | — | — | US | claimed |
| CN-118203574-A | Treatment of ocular diseases using endothelin receptor antagonists | 珀弗斯治疗股份有限公司 | 2024-06-18 | — | — | CN | claimed |
| EP-4094759-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | Perfuse Therapeutics, Inc. (US) | 2022-11-30 | — | — | EP | claimed |
| EP-4050997-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | Perfuse Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | claimed |
| US-20220257568-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | PERFUSE THERAPEUTICS, INC. | 2022-08-18 | — | — | US | claimed |
| US-20220257505-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | PERFUSE THERAPEUTICS, INC. | 2022-08-18 | — | — | US | claimed |
| CN-114786480-A | Treatment of ocular diseases using endothelin receptor antagonists | 珀弗斯治疗股份有限公司 | 2022-07-22 | — | — | CN | claimed |
| US-20260076948-A1 | TREATMENT OF DIABETIC RETINOPATHY USING ENDOTHELIN RECEPTOR ANTAGONISTS | PERFUSE THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12508284-B2 | Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250387325-A1 | FIXED DOSE COMBINATION OF BRIMONIDINE AND TIMOLOL | ALLERGAN INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250255810-A1 | OPHTHALMIC COMPOSITION | Sydnexis, Inc. | 2025-08-14 | — | — | US | disclosed |
| EP-4577642-A1 | PHOTORECEPTOR RESCUE CELL (PRC) COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR DISORDERS | Astellas Institute for Regenerative Medicine (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-119923464-A | Photoreceptor Rescue Cell (PRC) compositions and methods of treating ocular disorders | 安斯泰来再生医药协会 | 2025-05-02 | — | — | CN | disclosed |
| CN-114786480-A | Treatment of ocular diseases using endothelin receptor antagonists | 珀弗斯治疗股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-4026898-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-11382909-B2 | Ophthalmic composition | Sydnexis, Inc. (US) | 2022-07-12 | — | — | US | disclosed |
| WO-2022122937-A1 | NOVEL POLYMERS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-16 | — | — | WO | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-11241460-B2 | Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255810-A1 | OPHTHALMIC COMPOSITION | MYOC, PDE6H, PDE6C | ADRA2A 108/4885ADRA2B 214/4885ADRA2C 174/4885 |
| US-12508284-B2 | Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells | NR2E3, RARB, CHRNA10 | ADRA2A 593/4885ADRA2B 336/4885ADRA2C 450/4885 |
| US-20250099435-A1 | TREATMENT OF DIABETIC RETINOPATHY USING ENDOTHELIN RECEPTOR ANTAGONISTS | EDNRA, EDNRB, EDF1 | ADRA2A 107/4885ADRA2B 239/4885ADRA2C 393/4885 |
| US-20220257568-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | EDNRA, EDNRB, FLT1 | ADRA2A 84/4885ADRA2B 217/4885ADRA2C 421/4885 |
| US-11382909-B2 | Ophthalmic composition | MYOC, PDE6H, PDE6C | ADRA2A 108/4885ADRA2B 214/4885ADRA2C 174/4885 |
| US-20220257505-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | EDNRA, EDNRB, FLT1 | ADRA2A 104/4885ADRA2B 234/4885ADRA2C 393/4885 |
| US-20260076948-A1 | TREATMENT OF DIABETIC RETINOPATHY USING ENDOTHELIN RECEPTOR ANTAGONISTS | EDNRA, EDNRB, STRA6 | ADRA2A 239/4885ADRA2B 161/4885ADRA2C 400/4885 |
| US-20250387325-A1 | FIXED DOSE COMBINATION OF BRIMONIDINE AND TIMOLOL | PDE6D, PDE9A, PDE11A | ADRA2A 145/4885ADRA2B 45/4885ADRA2C 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.